- Home
- SST vs ACET Comparison
SST vs ACET Comparison
Compare SST & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | ACET |
|---|---|---|
| Founded | 2013 | 1947 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 69.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SST | ACET |
|---|---|---|
| Price | $2.85 | $7.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $65.33 |
| AVG Volume (30 Days) | 7.8K | ★ 161.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.45 |
| 52 Week High | $11.30 | $9.05 |
Technical Indicators
Market Signals| Indicator | SST | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 57.76 |
| Support Level | $0.34 | $7.70 |
| Resistance Level | $3.57 | $8.46 |
| Average True Range (ATR) | 0.26 | 0.46 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 17.11 | 96.30 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.